<DOC>
	<DOCNO>NCT00162695</DOCNO>
	<brief_summary>Objective study objective explore survival advantage intensify chemotherapy strategy randomise trial . IVA ( ifosfamide , vincristine , actinomycin D ) 6 drug combination ( IVA + carboplatin , epirubicin , etoposide ) deliver 27 week . Cumulative dose / m2 = ifosfamide 54g ( arm ) , epirubicin 450 mg , etoposide 1350 mg ( 6 drug ) . Delivery radiotherapy determine accord site / response chemotherapy Â± surgery . The study power detect 10 % difference 3 year OS .</brief_summary>
	<brief_title>Rhabdomyosarcoma Malignant Soft Tissue Tumours Childhood</brief_title>
	<detailed_description />
	<mesh_term>Rhabdomyosarcoma</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>age &gt; 6 month &lt; 18 year distant metastasis diagnosis within previous 8 week without prior treatment except surgery pathology available central review write consent accord institutional requirement stage III ( node positive ) stage I II non alveolar orbital tumour patient parameningeal disease age &lt; 3 year</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>September 2005</verification_date>
</DOC>